Credit: Metronom Health
Chinese medical device innovation hub Dinova Medtech and US-based medical device company Metronom Health have established a joint venture to develop and sell a continuous glucose monitoring system in China.
WHY IT MATTERS
Traditional fingerstick glucose meters can only provide information about intermittent glucose levels and the pain that comes with finger pricking can potentially reduce patients' adherence. By inserting a sensor into the subcutaneous tissue along with a transmitter that sends the data to a smart device, CGMs can provide continuous glucose information to detect glycemic variability.
According to a press release, Metronom Health has developed a minimally invasive CGM system that uses proprietary Opto-enzymatic technology – in contrast to most CGMs that use electrochemical technology – to capture both high and low ranges of a patient's glucose profile. The company claims that this will be done with "high" accuracy and also asserts that its device's sensor may last up to 14 days and reduce patient discomfort and infection risk.